Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2024

Open Access 01-12-2024 | Research

Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males

Authors: Dorte B. Zilstorff, Michael M. Richter, Jens Hannibal, Henrik L. Jørgensen, Henriette P. Sennels, Nicolai J. Wewer Albrechtsen

Published in: BMC Endocrine Disorders | Issue 1/2024

Login to get access

Abstract

Background

Glucagon is secreted from pancreatic alpha cells in response to low blood glucose and increases hepatic glucose production. Furthermore, glucagon enhances hepatic protein and lipid metabolism during a mixed meal. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are secreted from gut endocrine cells during meals and control glucose homeostasis by potentiating insulin secretion and inhibiting food intake.
Both glucose homeostasis and food intake have been reported to be affected by circadian rhythms and vice versa. In this study, we investigated whether the secretion of glucagon, GLP-1 and GIP was affected by circadian rhythms.

Methods

A total of 24 healthy men with regular sleep schedules were examined for 24 h at the hospital ward with 15 h of wakefulness and 9 h of sleep. Food intake was standardized, and blood samples were obtained every third hour. Plasma concentrations of glucagon, GLP-1 and GIP were measured, and data were analyzed by rhythmometric statistical methods. Available data on plasma glucose and plasma C-peptide were also included.

Results

Plasma concentrations of glucagon, GLP-1, GIP, C-peptide and glucose fluctuated with a diurnal 24-h rhythm, with the highest levels during the day and the lowest levels during the night: glucagon (p < 0.0001, peak time 18:26 h), GLP-1 (p < 0.0001, peak time 17:28 h), GIP (p < 0.0001, peak time 18:01 h), C-peptide (p < 0.0001, peak time 17.59 h), and glucose (p < 0.0001, peak time 23:26 h). As expected, we found significant correlations between plasma concentrations of C-peptide and GLP-1 and GIP but did not find correlations between glucose concentrations and concentrations of glucagon, GLP-1 and GIP.

Conclusions

Our results demonstrate that under meal conditions that are similar to that of many free-living individuals, plasma concentrations of glucagon, GLP-1 and GIP were observed to be higher during daytime and evening than overnight. These findings underpin disturbed circadian rhythm as a potential risk factor for diabetes and obesity.

Trial registration

ClinicalTrials.gov Identifier: NCT06166368. Registered 12 December 2023.
Literature
1.
go back to reference Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, Finan B, Gluud LL, Dean ED, Campbell JE, Bloom SR, Tan TM, Knop FK, et al. 100 years of glucagon and 100 more. Diabetologia. 2023;66(8):1378–94.CrossRefPubMed Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, Finan B, Gluud LL, Dean ED, Campbell JE, Bloom SR, Tan TM, Knop FK, et al. 100 years of glucagon and 100 more. Diabetologia. 2023;66(8):1378–94.CrossRefPubMed
2.
go back to reference Kraft G, Coate KC, Winnick JJ, Dardevet D, Donahue EP, Cherrington AD, Williams PE, Moore MC. Glucagon’s effect on liver protein metabolism in vivo. Am J Physiol Endocrinol Metab. 2017;313(3):E263-72.CrossRefPubMedPubMedCentral Kraft G, Coate KC, Winnick JJ, Dardevet D, Donahue EP, Cherrington AD, Williams PE, Moore MC. Glucagon’s effect on liver protein metabolism in vivo. Am J Physiol Endocrinol Metab. 2017;313(3):E263-72.CrossRefPubMedPubMedCentral
3.
go back to reference Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297(1–2):127–36.CrossRefPubMed Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297(1–2):127–36.CrossRefPubMed
4.
go back to reference Holst JJ, Albrechtsen NJW, Rosenkilde MM, Deacon CF. Physiology of the incretin hormones, GIP and GLP-1-regulation of release and posttranslational modifications. Compr Physiol. 2019;9(4):1339–81.CrossRefPubMed Holst JJ, Albrechtsen NJW, Rosenkilde MM, Deacon CF. Physiology of the incretin hormones, GIP and GLP-1-regulation of release and posttranslational modifications. Compr Physiol. 2019;9(4):1339–81.CrossRefPubMed
6.
go back to reference Kuhre RE, Wewer Albrechtsen NJ, Hartmann B, Deacon CF, Holst JJ. Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. J Diabetes Complications. 2015;29(3):445–50.CrossRefPubMed Kuhre RE, Wewer Albrechtsen NJ, Hartmann B, Deacon CF, Holst JJ. Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. J Diabetes Complications. 2015;29(3):445–50.CrossRefPubMed
9.
go back to reference Takahashi JS. Molecular architecture of the circadian clock in mammals. In: Sassone-Corsi P, Christen Y, editors. A time for metabolism and hormones. Cham: Springer Copyright 2016, The Author(s); 2016. p. 13–24.CrossRef Takahashi JS. Molecular architecture of the circadian clock in mammals. In: Sassone-Corsi P, Christen Y, editors. A time for metabolism and hormones. Cham: Springer Copyright 2016, The Author(s); 2016. p. 13–24.CrossRef
10.
go back to reference Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci. 2003;4(8):649–61.CrossRefPubMed Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci. 2003;4(8):649–61.CrossRefPubMed
11.
go back to reference Finger AM, Kramer A. Mammalian circadian systems: organization and modern life challenges. Acta Physiol (Oxf). 2021;231(3):e13548.CrossRefPubMed Finger AM, Kramer A. Mammalian circadian systems: organization and modern life challenges. Acta Physiol (Oxf). 2021;231(3):e13548.CrossRefPubMed
12.
go back to reference Liu C, Liu Y, Xin Y, Wang Y. Circadian secretion rhythm of GLP-1 and its influencing factors. Front Endocrinol (Lausanne). 2022;13:991397.CrossRefPubMed Liu C, Liu Y, Xin Y, Wang Y. Circadian secretion rhythm of GLP-1 and its influencing factors. Front Endocrinol (Lausanne). 2022;13:991397.CrossRefPubMed
13.
go back to reference Andriessen C, Schrauwen P, Hoeks J. The importance of 24-h metabolism in obesity-related metabolic disorders: opportunities for timed interventions. Int J Obes (Lond). 2021;45(3):479–90.CrossRefPubMed Andriessen C, Schrauwen P, Hoeks J. The importance of 24-h metabolism in obesity-related metabolic disorders: opportunities for timed interventions. Int J Obes (Lond). 2021;45(3):479–90.CrossRefPubMed
14.
go back to reference Jarrett RJ, Baker IA, Keen H, Oakley NW. Diurnal variation in oral glucose tolerance: blood sugar and plasma insulin levels morning, afternoon, and evening. Br Med J. 1972;1(5794):199–201.CrossRefPubMedPubMedCentral Jarrett RJ, Baker IA, Keen H, Oakley NW. Diurnal variation in oral glucose tolerance: blood sugar and plasma insulin levels morning, afternoon, and evening. Br Med J. 1972;1(5794):199–201.CrossRefPubMedPubMedCentral
15.
go back to reference Zimmet PZ, Wall JR, Rome R, Stimmler L, Jarrett RJ. Diurnal variation in glucose tolerance: associated changes in plasma insulin, growth hormone, and non-esterified fatty acids. Br Med J. 1974;1(5906):485–8.CrossRefPubMedPubMedCentral Zimmet PZ, Wall JR, Rome R, Stimmler L, Jarrett RJ. Diurnal variation in glucose tolerance: associated changes in plasma insulin, growth hormone, and non-esterified fatty acids. Br Med J. 1974;1(5906):485–8.CrossRefPubMedPubMedCentral
16.
go back to reference Mingrone G, Nolfe G, Gissey GC, Iaconelli A, Leccesi L, Guidone C, Nanni G, Holst JJ. Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion. Diabetologia. 2009;52(5):873–81.CrossRefPubMed Mingrone G, Nolfe G, Gissey GC, Iaconelli A, Leccesi L, Guidone C, Nanni G, Holst JJ. Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion. Diabetologia. 2009;52(5):873–81.CrossRefPubMed
17.
go back to reference Jones IR, Owens DR, Sarsons DL, Bloom SR. Day profiles of glucose dependent insulinotropic polypeptide (GIP) in normal subjects. Horm Metab Res. 1985;17(12):660–2.CrossRefPubMed Jones IR, Owens DR, Sarsons DL, Bloom SR. Day profiles of glucose dependent insulinotropic polypeptide (GIP) in normal subjects. Horm Metab Res. 1985;17(12):660–2.CrossRefPubMed
18.
go back to reference Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol. 1996;31(7):665–70.CrossRefPubMed Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol. 1996;31(7):665–70.CrossRefPubMed
19.
go back to reference Mari A, Gastaldelli A, Natali A, Ostergard T, Schmitz O, Ferrannini E. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests. Am J Physiol Endocrinol Metab. 2005;288(3):E541-546.CrossRefPubMed Mari A, Gastaldelli A, Natali A, Ostergard T, Schmitz O, Ferrannini E. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests. Am J Physiol Endocrinol Metab. 2005;288(3):E541-546.CrossRefPubMed
20.
go back to reference Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993;138(1):159–66.CrossRefPubMed Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993;138(1):159–66.CrossRefPubMed
21.
go back to reference Lindgren O, Mari A, Deacon CF, Carr RD, Winzell MS, Vikman J, Ahrén B. Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men. J Clin Endocrinol Metab. 2009;94(8):2887–92.CrossRefPubMed Lindgren O, Mari A, Deacon CF, Carr RD, Winzell MS, Vikman J, Ahrén B. Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men. J Clin Endocrinol Metab. 2009;94(8):2887–92.CrossRefPubMed
22.
go back to reference Sennels HP, Jørgensen HL, Fahrenkrug J. Diurnal changes of biochemical metabolic markers in healthy young males - the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest. 2015;75(8):686–92.CrossRefPubMed Sennels HP, Jørgensen HL, Fahrenkrug J. Diurnal changes of biochemical metabolic markers in healthy young males - the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest. 2015;75(8):686–92.CrossRefPubMed
23.
go back to reference Sennels HP, Jørgensen HL, Hansen AL, Goetze JP, Fahrenkrug J. Diurnal variation of hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest. 2011;71(7):532–41.CrossRefPubMed Sennels HP, Jørgensen HL, Hansen AL, Goetze JP, Fahrenkrug J. Diurnal variation of hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest. 2011;71(7):532–41.CrossRefPubMed
24.
go back to reference Kerkhof GA. Inter-individual differences in the human circadian system: a review. Biol Psychol. 1985;20(2):83–112.CrossRefPubMed Kerkhof GA. Inter-individual differences in the human circadian system: a review. Biol Psychol. 1985;20(2):83–112.CrossRefPubMed
28.
go back to reference Wewer Albrechtsen NJ, Mark PD, Terzic D, Hansen LH, Andersen U, Hartmann B, Carr RD, Gustafsson F, Deacon CF, Holst JJ, et al. Sacubitril/valsartan augments postprandial plasma concentrations of active GLP-1 when combined with sitagliptin in men. J Clin Endocrinol Metab. 2019;104(9):3868–76.CrossRefPubMed Wewer Albrechtsen NJ, Mark PD, Terzic D, Hansen LH, Andersen U, Hartmann B, Carr RD, Gustafsson F, Deacon CF, Holst JJ, et al. Sacubitril/valsartan augments postprandial plasma concentrations of active GLP-1 when combined with sitagliptin in men. J Clin Endocrinol Metab. 2019;104(9):3868–76.CrossRefPubMed
29.
go back to reference Kjeldsen SAS, Hansen LH, Esser N, Mongovin S, Winther-Sørensen M, Galsgaard KD, Hunt JE, Kissow H, Ceutz FR, Terzic D, et al. Neprilysin inhibition increases glucagon levels in humans and mice with potential effects on amino acid metabolism. J Endocr Soc. 2021;5(9):bvab084.CrossRefPubMedPubMedCentral Kjeldsen SAS, Hansen LH, Esser N, Mongovin S, Winther-Sørensen M, Galsgaard KD, Hunt JE, Kissow H, Ceutz FR, Terzic D, et al. Neprilysin inhibition increases glucagon levels in humans and mice with potential effects on amino acid metabolism. J Endocr Soc. 2021;5(9):bvab084.CrossRefPubMedPubMedCentral
30.
go back to reference Sharma A, Laurenti MC, Dalla Man C, Varghese RT, Cobelli C, Rizza RA, Matveyenko A, Vella A. Glucose metabolism during rotational shift-work in healthcare workers. Diabetologia. 2017;60(8):1483–90.CrossRefPubMedPubMedCentral Sharma A, Laurenti MC, Dalla Man C, Varghese RT, Cobelli C, Rizza RA, Matveyenko A, Vella A. Glucose metabolism during rotational shift-work in healthcare workers. Diabetologia. 2017;60(8):1483–90.CrossRefPubMedPubMedCentral
31.
go back to reference Gangwisch JE. Epidemiological evidence for the links between sleep, circadian rhythms and metabolism. Obes Rev. 2009;10 Suppl 2(0 2):37–45.CrossRefPubMed Gangwisch JE. Epidemiological evidence for the links between sleep, circadian rhythms and metabolism. Obes Rev. 2009;10 Suppl 2(0 2):37–45.CrossRefPubMed
32.
go back to reference Gonnissen HK, Hursel R, Rutters F, Martens EA, Westerterp-Plantenga MS. Effects of sleep fragmentation on appetite and related hormone concentrations over 24 h in healthy men. Br J Nutr. 2013;109(4):748–56.CrossRefPubMed Gonnissen HK, Hursel R, Rutters F, Martens EA, Westerterp-Plantenga MS. Effects of sleep fragmentation on appetite and related hormone concentrations over 24 h in healthy men. Br J Nutr. 2013;109(4):748–56.CrossRefPubMed
33.
go back to reference Lunn RM, Blask DE, Coogan AN, Figueiro MG, Gorman MR, Hall JE, Hansen J, Nelson RJ, Panda S, Smolensky MH, et al. Health consequences of electric lighting practices in the modern world: a report on the National Toxicology Program’s workshop on shift work at night, artificial light at night, and circadian disruption. Sci Total Environ. 2017;607–608:1073–84.ADSCrossRefPubMedPubMedCentral Lunn RM, Blask DE, Coogan AN, Figueiro MG, Gorman MR, Hall JE, Hansen J, Nelson RJ, Panda S, Smolensky MH, et al. Health consequences of electric lighting practices in the modern world: a report on the National Toxicology Program’s workshop on shift work at night, artificial light at night, and circadian disruption. Sci Total Environ. 2017;607–608:1073–84.ADSCrossRefPubMedPubMedCentral
Metadata
Title
Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
Authors
Dorte B. Zilstorff
Michael M. Richter
Jens Hannibal
Henrik L. Jørgensen
Henriette P. Sennels
Nicolai J. Wewer Albrechtsen
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2024
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-024-01566-9

Other articles of this Issue 1/2024

BMC Endocrine Disorders 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine